Anti-GM-CSF Otilimab Versus Tofacitinib or Placebo in Patients with Active Rheumatoid Arthritis and an Inadequate Response to Conventional or Biologic DMARDs: Two Phase 3 Randomised Trials (contrast 1 and Contrast 2).
Annals of the Rheumatic Diseases（2023）
关键词
rheumatoid arthritis,autoimmune diseases,biological therapy,cytokines,inflammation
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要